Opendata, web and dolomites

ZENEO

ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ZENEO project word cloud

Explore the words cloud of the ZENEO project. It provides you a very rough idea of what is the project "ZENEO" about.

suddenly    suffer    zeneo    counteract    airways    36    europeans    shock    hospitalizations    q4    reaction    adrenaline    anaphylaxis    free    last    anyone    injector    food    billion    player    someone    risk    relatives    estimate    generate    plan    quick    needle    oxygen    minutes    close    profit    prone    aged    performs    turnover    roi    syringes    properly    serious    crossject    inject    guarantees    solution    right    company    launch    happen    room    million    suitable    emergency    enter    heart    death    commercialization    prefilled    innovative    line    market    cutting    reactions    anaphylactic    threatening    filled    young    life    create    sends    allergy    124m    device    allergic    payback    guarantee    administer    2021    seventeen    136m    injection    total    discomfort    situations    intramuscular    worldwide    adults    contamination    14    huge    patients    avoiding    jobs    people    fifth    autoinjectors    edge    28    reg    big    auto    causes    allergies    revenues    children   

Project "ZENEO" data sheet

The following table provides information about the project.

Coordinator
CROSSJECT 

Organization address
address: 6 RUE PAULINE KERGOMARD ZAC PARC MAZEN SULLY
city: DIJON
postcode: 21000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.crossject.com/en
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CROSSJECT FR (DIJON) coordinator 50˙000.00

Map

 Project objective

Anaphylactic shock is a serious, life-threatening allergic reaction in which the airways suddenly close; if not properly treated it causes death in 20 minutes. Seventeen million Europeans suffer from food allergies, 3.5 million which are children or young adults. Across Europe, food allergy is the leading cause of anaphylaxis in children aged 0-14 years and there is a huge increase in hospitalizations for allergic reactions in children in the last 10 years. Anaphylaxis sends someone to the emergency room every 3 minutes. The only way to counteract an anaphylactic shock is to inject adrenaline to guarantee enough oxygen to the heart. The adrenaline market is estimated to create revenues of €1.2 billion worldwide, and there is only one big player that produce prefilled syringes. Crossject already has the know-how to produce pre-filled needle free autoinjectors, our ZENEO® line. We already have 4 ZENEO® products so we are the right company to enter the adrenaline market with a cutting-edge solution. ZENEO® Adrenaline is an innovative, needle-free, easy-to-use auto-injector suitable for emergency situations, that enables patients and relatives to administer adrenaline. It performs a quick injection (1/10 of a second) avoiding the needle-related discomfort and the risk of contamination, moreover it guarantees intramuscular injection. The end-users of our product are people that are having an anaphylactic shock. People with food allergies are those that will need our device the most as they are more prone to anaphylaxis, however an anaphylactic shock can happen to anyone. We plan to launch ZENEO® Adrenaline on the market in Q4 2021. We will a turnover of €136M and a profit of €124M by the fifth year of commercialization. We expect to achieve the payback between the second and the third year of commercialization and to generate ROI of 3.36 by the fifth year of commercialization. Moreover, we estimate to create a total of 28 new jobs during these 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ZENEO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ZENEO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More